已收盘 12-19 16:00:00 美东时间
+0.100
+0.82%
Fulcrum Therapeutics stock surges on Monday after releasing positive results from Phase 1b trial of pociredir in sickle cell disease.
12-09 02:06
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
12-09 01:46
FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically
12-08 20:34
Fulcrum Therapeutics granted 70,000 stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The options have an exercise price of $6.96 per share, vest over four years, and expire in ten years. The company specializes in developing small molecules for rare genetic diseases.
06-06 20:30
Fulcrum Therapeutics announced that its management will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 11, 2025. The event will be webcast and available on the company’s website for 30 days.
05-29 12:30
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 66.4% to $6...
2024-09-27 00:31
In the preceding three months, 7 analysts have released ratings for Fulcrum The...
2024-09-13 21:00
U.S. stocks traded higher toward the end of trading, with the Dow Jones index s...
2024-09-13 02:01
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
2024-09-13 00:10